U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H20N2.2C16H18N2O4S.4H2O
Molecular Weight 981.185
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PENICILLIN G BENZATHINE

SMILES

O.O.O.O.C(CNCC1=CC=CC=C1)NCC2=CC=CC=C2.CC3(C)S[C@@H]4[C@H](NC(=O)CC5=CC=CC=C5)C(=O)N4[C@H]3C(O)=O.CC6(C)S[C@@H]7[C@H](NC(=O)CC8=CC=CC=C8)C(=O)N7[C@H]6C(O)=O

InChI

InChIKey=WIDKTXGNSOORHA-CJHXQPGBSA-N
InChI=1S/2C16H18N2O4S.C16H20N2.4H2O/c2*1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;1-3-7-15(8-4-1)13-17-11-12-18-14-16-9-5-2-6-10-16;;;;/h2*3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);1-10,17-18H,11-14H2;4*1H2/t2*11-,12+,14-;;;;;/m11...../s1

HIDE SMILES / InChI

Molecular Formula C16H18N2O4S
Molecular Weight 334.39
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C16H20N2
Molecular Weight 240.3434
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Penicillin G, also known as benzylpenicillin, is a penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms. Microbiology Penicillin G is bactericidal against penicillin-susceptible microorganisms during the stage of active multiplication. It acts by inhibiting biosynthesis of cell-wall mucopeptide. It is not active against the penicillinase-producing bacteria, which include many strains of staphylococci. Penicillin G is highly active in vitro against staphylococci (except penicillinase-producing strains), streptococci (groups A, B, C, G, H, L and M), pneumococci and Neisseria meningitidis. Other organisms susceptible in vitro to penicillin G are Neisseria gonorrhoeae, Corynebacterium diphtheriae, Bacillus anthracis, clostridia, Actinomyces species, Spirillum minus, Streptobacillus monillformis, Listeria monocytogenes, and leptospira; Treponema pallidum is extremely susceptible. Adverse effects can include hypersensitivity reactions including urticaria, fever, joint pains, rashes, angioedema, anaphylaxis, serum sickness-like reaction.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
PENICILLIN G SODIUM

Approved Use

Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued

Launch Date

2001
Curative
PENICILLIN G SODIUM

Approved Use

Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued

Launch Date

2001
Curative
PENICILLIN G SODIUM

Approved Use

Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued

Launch Date

2001
Primary
PENICILLIN G SODIUM

Approved Use

Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued

Launch Date

2001
Primary
PENICILLIN G SODIUM

Approved Use

Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued

Launch Date

2001
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
400 μg/mL
5000000 unit single, intravenous
dose: 5000000 unit
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PENICILLIN G serum
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.1 day
1200000 unit single, intramuscular
dose: 1200000 unit
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PENICILLIN G serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
65%
12000000 unit 1 times / day steady-state, intravenous
dose: 12000000 unit
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
PENICILLIN G plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
40%
PENICILLIN G serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The optimization test in the guinea-pig. A method for the predictive evaluation of the contact allergenicity of chemicals.
1975 May
Penicillin-induced haemolytic anaemia associated with microangiopathy.
1976 Apr
Fresh vs aged benzylpenicillin on non-IgE responses in mice.
1998 Jan
Penicillin and cephalosporin biosynthesis: mechanism of carbon catabolite regulation of penicillin production.
1999 Jan-Feb
Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain.
1999 May 7
Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae.
1999 Oct
Haemorrhagic cystitis and renal dysfunction associated with high dose benzylpenicillin.
2000 Jan
Drug-induced hemolysis: cefotetan-dependent hemolytic anemia mimicking an acute intravascular immune transfusion reaction.
2000 May
Routine prophylactic antibiotic use in the management of snakebite.
2001
Optimisation of the prevention and treatment of bacterial endocarditis.
2001
[Epidemiological survey for hemolytic streptococci isolated from children in Tokyo].
2001 Apr
Substrate binding and catalytic mechanism of class B beta-lactamases: a molecular modelling study.
2001 Dec
[In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae].
2001 Jul
Epidemiology and diagnosis of meningitis: results of a five-year prospective, population-based study.
2001 Jun
Application of ion-exchange cartridge clean-up in food analysis IV. Confirmatory assay of benzylpenicillin, phenoxymethylpenicillin, oxacillin, cloxacillin, nafcillin and dicloxacillin, in bovine tissues by liquid chromatography-electrospray ionization tandem mass spectrometry.
2001 Mar 16
[The use of veterinary drugs during pregnancy of the dog].
2001 Nov 15
Purification and characterization of a beta-lactamase from Haemophilus ducreyi in Escherichia coli.
2001 Oct
Antibiotic usage in Nordic countries.
2001 Sep
The VanY(D) DD-carboxypeptidase of Enterococcus faecium BM4339 is a penicillin-binding protein.
2001 Sep
The penicillin resistance of Enterococcus faecalis JH2-2r results from an overproduction of the low-affinity penicillin-binding protein PBP4 and does not involve a psr-like gene.
2001 Sep
[Allergic alteration of leukocytes in patients with drug intolerance].
2001 Sep-Oct
[Benzylpenicillin efficacy for neutropenic infection prophylaxis in patients with cancer and postcytostatic neutropenia].
2002
Treatment of amatoxin poisoning: 20-year retrospective analysis.
2002
Antibiotics differ in their tendency to cause infusion phlebitis: a prospective observational study.
2002
3: Community-acquired pneumonia.
2002 Apr 1
Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from Mycobacterium tuberculosis.
2002 Feb 1
Liquid chromatographic determination of ampicillin residues in porcine muscle tissue by a multipenicillin analytical method: European Collaborative Study.
2002 Jul-Aug
Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy.
2002 Jun
Characterization of specific IgE response in vitro against protein and drug allergens using atopic and normal donors.
2002 Mar
Evaluation of the new VITEK 2 system for determination of the susceptibility of clinical isolates of Streptococcus pneumoniae.
2002 Mar
[Use of antibiotics in general practice and at the Clinic for Infectious Diseases].
2002 May-Jun
beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin.
2002 Nov
Minimum inhibitory concentrations of 20 antimicrobial agents against Staphylococcus aureus isolated from bovine intramammary infections in Japan.
2002 Nov
[Antimicrobial susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolated in major hospitals in Nagano Prefecture].
2002 Oct
Benzylpenicillin differentially conjugates to IFN-gamma, TNF-alpha, IL-1beta, IL-4 and IL-13 but selectively reduces IFN-gamma activity.
2003 Feb
High-performance thin-layer chromatography-bioautography for multiple antibiotic residues in cow's milk.
2003 Feb 5
Insights into the acylation mechanism of class A beta-lactamases from molecular dynamics simulations of the TEM-1 enzyme complexed with benzylpenicillin.
2003 Jan 22
Patents

Sample Use Guides

Serious infections due to susceptible strains of streptococci (including S. pneumoniae): 5 to 24 million units/day depending on the infection and its severity administered in equally divided doses every 4 to 6 hours Anthrax: Minimum of 8 million units/day in divided doses every 6 hours. Higher doses may be required depending on susceptibility of organism Actinomycosis: 1 to 6 million units/day Diphtheria (adjunctive therapy to antitoxin and for the prevention of the carrier state): 2 to 3 million units/day in divided doses for 10 to 12 days Listeria infections, Meningitis: 15 to 20 million units/day for 2 weeks
Route of Administration: Other
It was studied the antioxidant activity of penicillin G (PG) through its reactivity towards reactive oxygen species (superoxide anion radical, O2•̅; hydroxyl radical, HO• ; peroxyl radical, ROO• ; hydrogen peroxide, H2 O2 ; DPPH• ) using various in vitro antioxidant assays with chemiluminescence (CL) and spectrophotometry as measurement techniques. In hydroxyl radical assays , PG was found to inhibit the CL signal arising from the Fenton-like reaction in a dose-dependent manner with IC50 = 0.480 ± 0.020 mM. The highest reactivity of PG among the tested penicillins towards the HO radical was confirmed in the deoxyribose degradation assay.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:34:03 GMT 2025
Edited
by admin
on Mon Mar 31 17:34:03 GMT 2025
Record UNII
RIT82F58GK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PENICILLIN G BENZATHINE
GREEN BOOK   MI   ORANGE BOOK   USP   USP-RS   VANDF  
Common Name English
BENZATHINE BENZYLPENICILLIN
MART.  
Preferred Name English
PENICILLIN G BENZATHINE [GREEN BOOK]
Common Name English
BENZATHINE BENZYLPENICILLIN [MART.]
Common Name English
PENICILLIN G BENZATHINE [USP-RS]
Common Name English
BENZATHINE BENZYLPENICILLIN TETRAHYDRATE
Common Name English
BENZATHINE PENICILLIN
Common Name English
PERMAPEN
Brand Name English
PENICILLIN G BENZATHINE [USP MONOGRAPH]
Common Name English
BENZYLPENICILLIN BENZATHINE
Common Name English
(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENYLACETAMIDO)-4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID COMPOUND WITH N,N'-DIBENZYLETHYLENEDIAMINE (2:1), TETRAHYDRATE
Common Name English
PENICILLIN G BENZATHINE [USP IMPURITY]
Common Name English
BICILLIN C-R COMPONENT PENICILLIN G BENZATHINE
Common Name English
BENZYLPENICILLIN BENZATHINE HYDRATE [JAN]
Common Name English
BENZYLPENICILLIN BENZATHINE HYDRATE
JAN  
Common Name English
PENICILLIN G BENZATHINE [VANDF]
Common Name English
PENICILLIN G BENZATHINE [ORANGE BOOK]
Common Name English
PENICILLIN G BENZATHINE [MI]
Common Name English
BICILLIN
Brand Name English
4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 3,3-DIMETHYL-7-OXO-6-((PHENYLACETYL)AMINO)-, (2S-(2.ALPHA.,5.ALPHA.,6.BETA.))-, COMPD. WITH N,N'-BIS(PHENYLMETHYL)-1,2-ETHANEDIAMINE (2:1), TETRAHYDRATE
Common Name English
Classification Tree Code System Code
WHO-ESSENTIAL MEDICINES LIST 6.2.1
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
WHO-ATC J01CE08
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
CFR 21 CFR 522.1696A
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
WHO-VATC QJ51RC24
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
NCI_THESAURUS C1500
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
WHO-VATC QJ01CE08
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
Code System Code Type Description
DAILYMED
RIT82F58GK
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
DRUG CENTRAL
4347
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
LACTMED
Benzathine Penicillin G
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
ChEMBL
CHEMBL29
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
MESH
D010401
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
RS_ITEM_NUM
1502009
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
EVMPD
SUB37626
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
EPA CompTox
DTXSID00194317
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
FDA UNII
RIT82F58GK
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
RXCUI
7982
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY RxNorm
SMS_ID
100000129194
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
PUBCHEM
656811
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
MERCK INDEX
m8475
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY Merck Index
CAS
41372-02-5
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
WIKIPEDIA
BENZATHINE BENZYLPENICILLIN
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
NCI_THESAURUS
C47657
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
DRUG BANK
DBSALT002769
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
CHEBI
51352
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
EVMPD
SUB05741MIG
Created by admin on Mon Mar 31 17:34:03 GMT 2025 , Edited by admin on Mon Mar 31 17:34:03 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY